Long non‑coding RNA CASC9/microRNA‑590‑3p axis participates in lutein‑mediated suppression of breast cancer cell proliferation
- Yuxia Zhang
- Jingzhi Chang
- Weiwei Jiang
- Xin Ye
- Shanfeng Zhang
Affiliations: Department of Biochemistry and Molecular Biology, Shangqiu Medical College, Shangqiu, Henan 476100, P.R. China, Department of Medical College, Shangqiu Institute of Technology, Shangqiu, Henan 476400, P.R. China, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China
- Published online on: May 20, 2021 https://doi.org/10.3892/ol.2021.12805
Copyright: © Zhang
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Previous studies have shown that lutein can inhibit the proliferation of breast cancer cells. However, the mechanism of lutein inhibiting the proliferation of breast cancer cells remains unclear. The present study aimed to determine whether the long non‑coding RNA (lncRNA) Cancer Susceptibility 9 (CASC9)/microRNA (miR)‑590‑3p axis participates in the antiproliferative effects of lutein via lncRNA microarray hybridization, reverse transcription‑quantitative PCR, dual‑luciferase reporter and MTT assays. The results demonstrated that CASC9 was the most significantly downregulated lncRNA in MCF7 cells treated with lutein. miR‑590‑3p was identified as the target of CASC9. In addition, lutein downregulated CASC9 expression and upregulated miR‑590‑3p expression in dose‑ and time‑dependent manners, respectively. CASC9 knockdown or overexpression of miR‑590‑3p inhibited the proliferation of breast cancer cells. Notably, simultaneous transfection with miR‑590‑3p mimics and CASC9 small interfering RNA increased the potency of lutein in inhibiting the proliferation of breast cancer cells. Taken together, these results suggest that the CASC9/miR‑590‑3p axis participates in the antiproliferative effects of lutein on breast cancer.